Arvinas is a biotechnology company developing small-molecule therapies based on targeted protein degradation (PROTAC) technology, which selectively degrades disease-causing proteins inside cells to treat cancer and metabolic diseases. The company operates through a hybrid model combining internal research and development with strategic partnerships, including collaborations with Pfizer on its lead breast cancer candidate and with Novartis on a metabolic disease program, generating revenue through milestone payments and royalties. For approved candidates outside its partnerships, Arvinas plans to build its own specialized U.S. commercial organization, though it relies on contract research organizations and manufacturers for development and manufacturing execution.